Treace
Designs and markets bunion correction systems
Sales Representative
Requires local travel up to 90% and overnight travel up to 20%.
About the job
- A Bachelor’s degree and at least 2 years of successful field sales experience.
- The ability to travel locally (up to 90%) and overnight (up to 20%).
- Experience supporting surgeons in operating room environments.
- Hospital credentialing readiness and the capability to manage emergency support scenarios.
- A valid driver’s license and current vehicle insurance.
- Deliver Impact: Become a subject matter expert in Treace Medical’s products and procedures, supporting surgeons and operating room teams for optimal patient outcomes.
- Strategize for Growth: Build and maintain new customer relationships, follow up on company-generated leads, and drive customer conversion consistently.
- Provide Feedback to Innovate: Collaborate with the marketing team to enhance product design and improve user satisfaction.
- Train for Excellence: Plan, coordinate, and execute product training for surgeons in both didactic and hands-on (cadaveric) settings.
- Foster Relationships: Maintain strong links with key accounts to further sales, expand market development, and ensure service continuity.
About the company
Treace Medical Concepts designs, manufactures, and markets orthopedic surgical systems for foot and ankle care, focusing on bunion correction and midfoot deformities. Its flagship Lapiplasty 3D Bunion Correction System uses patented instruments, implants, and a multi-plane approach with Biplanar plating to correct bunions at the root and enable faster weight-bearing. The company also offers Adductoplasty for coexisting midfoot deformities, Hammertoe PEEK Fixation, and SpeedPlate bone-fusion systems, selling kits through a direct sales force and distributors to physicians, ambulatory surgery centers, and hospitals. Treace aims to grow its portfolio and market leadership in foot-and-ankle devices by expanding adoption and improving surgical outcomes.
Company Size
201-500
Company Stage
IPO
Headquarters
Ponte Vedra Beach, Florida
Founded
2014
Get referred to Treace
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 case volumes grew high single digits, and 40% of surgeons adopted new systems.
- Management raised 2026 revenue guidance to $204 million-$212 million on August 7, 2026.
- SuperBite and HyperPlate XM reached first cases in 2026, broadening addressable market $300 million.
What critics are saying
- Q2 2026 revenue fell 4%, and lower-priced products still pressure margins.
- Treace finished June 2026 with $45.6 million cash, while growth depends on Q3 launches.
- If Lapiplasty share erodes, Treace becomes a commoditized foot-and-ankle kit vendor.
What makes Treace unique
- Treace’s Lapiplasty owns a patented 3D bunion workflow surgeons already know.
- September 2026 AOFAS launches extend one salesforce across bunions, midfoot, hindfoot, and fusions.
- Cloud X-ray, SuperBite, and HyperPlate create a stickier, procedure-spanning surgeon platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Parental Leave
401(k) Company Match
Company Equity
Unlimited Paid Time Off
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↑ 0%Treace Medical Concepts will showcase new product innovations and present clinical data at the American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle from 16 to 19 September 2026. The medical technology company will feature several technologies aimed at advancing its leadership in the bunion market whilst extending its reach into the mid and hindfoot market. New products include the Lapiplasty Lightning System with next-generation instrumentation, the Tailorplasty MIS Tailor's Bunion System for minimally invasive treatment, and a cloud-based X-ray app for radiographic measurements. The company will also present innovations for mid and hindfoot markets, including SuperBite compression screws, the HyperPlate XM dynamic compression locking implant, CartiBlaster powered joint prep instruments, and VitaFuse bioactive glass graft.
Treace highlights product innovations and Clinical Data across its expanding Foot & Ankle portfolio at the 2026 AOFAS Annual Meeting. New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies. PONTE VEDRA, Fla., Sept. 15, 2026 (GLOBE NEWSWIRE) - Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced it will highlight multiple new product innovations and present clinical data at the American Orthopaedic Foot & Ankle Society ("AOFAS") Annual Meeting in Seattle, Washington from September 16-19, 2026. "We are excited to showcase our expanding portfolio of best-in-class foot & ankle innovations at AOFAS 2026," said John T. Treace, CEO, Founder and Chairman of Treace. "This year, we will be featuring several new technologies aimed at advancing our leadership in the bunion market, while also extending our reach into the mid and hindfoot market which allows us to more comprehensively service our surgeon customers' needs." Technologies to be featured in surgeon training events and at Treace's AOFAS exhibit booth: Latest Advancements to Treace's Market-Leading 3D Bunion Correction Portfolio * Lapiplasty(R) Lightning(TM) System: Featuring next-generation instrumentation to accompany the SpeedTMT(R) implant technology, designed to provide surgeons with ultimate control of their 3D bunion correction, while reducing surgical steps for a faster procedure. * Tailorplasty(TM) MIS Tailor's Bunion System: A minimally invasive solution for the surgical treatment of tailor's bunions, or "bunionettes", which are painful deformities of the 5th metatarsal estimated to affect approximately 5-10% of the adult population. * Treace(TM) X-ray App: Cloud-based software for making radiographic measurements in foot and ankle X-rays, putting anatomical measurements at the fingertips of surgeons. New Innovations Expanding Treace's Reach into the Mid and Hindfoot Markets * SuperBite(TM) Fully-Threaded Compression Screws: Comprehensive system of self-drilling screws designed to reduce steps and save time in fusion and osteotomy procedures, addressing a broad range of foot & ankle applications across the forefoot, midfoot, and hindfoot. * HyperPlate(TM) XM Dynamic Compression Locking Implant: Advanced fixation construct combining locking screws and dynamic compression for a highly stable construct with an anatomic shape designed to promote fusion in the larger bones of the midfoot and hindfoot. * CartiBlaster(TM) Powered Joint Prep instruments: Sterile, single-use instruments designed for fast and controlled cartilage removal and joint preparation in fusion procedures throughout the midfoot and hindfoot. * VitaFuse(TM) Bioactive Glass Graft: A new synthetic bone graft technology that expands our growing biologics portfolio, which includes our tissue-based CortiFuse(TM) graft and procedure specific wedges. Results highlighting the clinical performance of Treace technologies in the landmark 5-year ALIGN3D(R) Lapiplasty(R), MTA3D(TM) Adductoplasty(R) and SPRINT(TM) SpeedPlate(R) studies will be presented during the AOFAS Annual Meeting. Clinical Data Presentation Schedule * Friday, September 18 at 8:45am PST: The ALIGN3D(R) Lapiplasty(R) clinical study podium presentation, "Five-Year Analysis of a Prospective Multicenter Study of Triplanar Tarsometatarsal Arthrodesis With Early Weightbearing: Radiographic, Clinical and Patient Reported Outcomes", will be presented by Daniel Farber, MD, Lehigh Valley Orthopedic Institute (Bethlehem, PA). * Thursday, September 17 at 4:00pm PST: The MTA3D(R) Adductoplasty(R) clinical study podium presentation, "Radiographic and Patient-Reported Outcomes Following Combined Metatarsus Adductus and Hallux Valgus Correction with Early Weightbearing - 2-year Interim results of a Multicenter Prospective Study", will be presented by Mark Easley, MD, Duke University (Durham, NC). * Audio poster presentation: The SPRINT(TM) SpeedPlate(R) observational clinical study, "Radiographic and Patient-Reported Outcomes Following Joint Arthrodesis in the Foot Using a Novel, Dynamic Compression Implant System", will be presented by Jody McAleer, DPM, Jefferson City Medical Group (Jefferson City, MO). About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty(R) 3D Bunion Correction(R) System - a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty(R) Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty(R) 3D Minimally Invasive Bunion Correction System and the Percuplasty(R) Percutaneous 3D Bunion Correction System, and the SpeedMTP(R) 1st MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate(R) rapid compression implant platform to new applications, providing surgeons with advanced digital solutions with its IntelliGuide(R) patient specific, pre-op planning and cut guide technology, and offering SuperBite(TM) Fully-Threaded Compression Screws for use in fusions throughout the foot. For more information, please visit www.treace.com. Treace Medical Concepts Mark L. Hair Chief Financial Officer [email protected] (904) 373-5940 Investors: Gilmartin Group Philip Trip Taylor [email protected]
Treace Medical Concepts reported Q2 2026 revenue of $45.4 million, down 4% year-over-year, driven by lower distributor sales and a shift to lower-priced products. Gross margin declined to 78.5% from 79.7% in the prior year period. Despite the revenue decline, the company narrowed its net loss to $15.9 million, or $0.24 per share, compared to $17.4 million a year earlier. Operating expenses fell 8% to $50.6 million. Cash usage dropped 57% year-to-date. Case volume growth accelerated to high single digits as 40% of Lapiplasty surgeons adopted at least one of three new bunion systems. The company raised full-year revenue guidance to $204 million to $212 million, representing a decline of 0% to 4% versus 2025. Cash and marketable securities totalled $45.6 million as of 30 June 2026.
Treace Medical Concepts has completed the first surgical case using its HyperPlate XM Dynamic Compression Locking Implant System. The device combines FastPitch locking screws with titanium compression implants to deliver rapid insertion and dynamic compression for midfoot and hindfoot procedures. Dr Paul Dayton of the Foot & Ankle Center of Iowa performed the inaugural procedure, a talonavicular joint fusion. He praised the implant's anatomic fit and stability, noting that the accompanying GreatReleaseXM Rapid Release Instrument improved surgical efficiency. The system features an ultra-low profile design for procedures including talonavicular, calcaneocuboid, naviculocuneiform and tarsometatarsal fusions, plus Evans calcaneal osteotomies. Full commercialisation is expected in the third quarter of 2026, expanding Treace's bunion and midfoot portfolio into a larger addressable market.
Treace to present at the Sidoti Small Cap Conference. PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) - Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will present at the Sidoti Small Cap Conference, Thursday, June 18, 2026, beginning at approximately 1:45 pm ET. A live webcast and replay of the presentation will be available on the Company's investors relations website at https://investors.treace.com/. Internet Posting of Information Treace routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace. About Treace Medical Concepts Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty(R) 3D Bunion Correction(R) System - a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty(R) Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty(R) 3D Minimally Invasive Bunion Correction System and the Percuplasty(TM) Percutaneous 3D Bunion Correction System, and the SpeedMTP(R) MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate(R) rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide(R) patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com. Contacts: Treace Medical Concepts Mark L. Hair Chief Financial Officer [email protected] (904) 373-5940 Investors: Gilmartin Group Philip Trip Taylor [email protected] Company Profile Treace Medical Concepts, Inc. Industry: Medical Equipment Website: https://treace.com Recommended reading.